Tria™ Ureteral Stent

Tria™ Ureteral Stent

Unlike any other.​

What makes Tria unlike any other?​

When it comes to ureteral stents, urine calcium (Ca) and magnesium (Mg) salt deposits can contribute to stent complications such as encrustation.1,2  The cause and rate of encrustation is multifactorial and can include factors such as body chemistry and medical condition of the patient, stent indwell time, and surface material or properties of the stent.2-4 The Tria stent may help control the accumulation of Mg and Ca salts.5-6​

Furthermore, the Tria Stent is designed to be stiffer during placement to navigate patient anatomy while softening by over 40% at body temperature, which may promote greater patient tolerability.7​

References

  1. Bruce AW, Sira SS, Clark AF, et al. The problem of catheter encrustation. Can Med Assoc J. 1974 Aug 3;111(3):238-41.
  2. Vanderbrink BA, Rastinehad AR, Ost MC, et al. Encrusted urinary stents: evaluation and endourologic management. J Endourol. 2008 May;22(5):905-12.
  3. Bultitude MF, Tiptaft RC, Glass JM, et al. Management of encrusted ureteral stents impacted in upper tract. Urology. 2003 Oct;62(4):622-6.
  4. Elwood CN, Lo J, Chou E, et al. Understanding urinary conditioning film components on ureteral stents: profiling protein components and evaluating their role in bacterial colonization. Biofouling. 2013;29(9):1115-22.
  5. Data on file with Boston Scientific. Bench test results may not necessarily be indicative of clinical performance.
  6. Study methodology: Testing was performed by an independent third-party using the in-vitro BEST™ method to evaluate salt adhesion of the ureteral stents. A total of 30 samples from each ureteral stent family were tested in both a sterile Artificial Urine Model and a Bacterial Infection Model (n=15 in each model) for 2 weeks. Proteus mirabilis was used as the microbial challenge in the Bacterial Infection Model due to its known urease production and involvement in struvite formation.
  7. Park HK, Paick SH, Kim HG, et al. The impact of ureteral stent type on patient symptoms as determined by the ureteral stent symptom questionnaire: A prospective, randomized, controlled study. J Endourol. 2015 Mar;29(3): 367-71.

Disclaimers
When discussing the stone management portfolio, claims apply to one or more products that could meet the needs of the patient and/or provider. Refer to associated references for applicable products.
The testing was performed by or on behalf of BSC. Data on file.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products are shown for INFORMATION purposes only and may not be approved or for sale in certain countries. Rx only.
This material is not intended for use in France. For product availability in your country please check with your local Boston Scientific representative. Kidney stone pictures are for illustrative purposes only. Source: Getty Images and Adobe Stock. 
All other images are the property of Boston Scientific.
All trademarks are the property of their respective owners.

Indications, Safety and Warnings